SoracteLite Micro-Invasive Treatment for BPH

Prostatic tissue ablation, with transperineal approach, not even touching the urethra.

Benign Prostatic Hyperplasia causes problems that, if not properly treated, have a strong impact on a patient’s quality of life.

SoracteLite is an innovative and micro-invasive treatment for BPH. It is a non-surgical procedure.
SoracteLite is an alternative treatment to surgery and other mini-invasive techniques that use a transurethral approach. SoracteLite treatment consists of the percutaneous insertion of optical bers (one or two bers per lobe depending on the basal volume of the prostatic gland) via transperineal access.

SoracteLite uses low-power laser energy (typically 3 Watts) for a few minutes: laser radiation is transmitted by means of optical bres inserted percutaneously in the organ through extremely thin needles. The portion of thermally treated tissue is naturally reabsorbed by the gland in the following weeks, resulting in a reduction in the prostate volume and the resolution of symptoms.

Type of approach: SoracteLite is the only treatment that uses a transperineal approach, with the insertion of very thin needles to reach the area to be treated, thus avoiding traumatic interactions with the last section of the urinary tract (urethra and bladder) and the complications often associated with the transurethral approach.

• The short duration of treatment, low dose of energy
• No prostate tissue removal: No risk of bleeding
• Non-surgical treatment: No risk of sexual complications
• No general or loco-regional (spinal) anesthesia
• No complications to the urethra
• Reduced hospitalization (day hospital procedure)